Amy Meng

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Paqui G. Través, Bernard P. Murray, Federico Campigotto et al. · Annals of the Rheumatic Diseases · 2021 · 333 citations · Full text

Medicine, Internal Medicine, Pharmacology +16

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis

Sergio Borgia, Janet Dearden, Eric M. Yoshida et al. · Journal of Hepatology · 2019 · 123 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Phase 1 First‐in‐Human, Single‐ and Multiple‐Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection

Polina German, Yan Xin, Jason W. Chien et al. · The Journal of Clinical Pharmacology · 2018 · 15 citations

Medicine, Infectious Diseases, Pharmacology +10

Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies

Amy Meng, Kacey Anderson, Cara Nelson et al. · British Journal of Clinical Pharmacology · 2022 · 10 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17